Safety and tolerability
Somatuline® Depot (lanreotide) Injection is generally well-tolerated therapy with a low discontinuation rate
Only 1.9% of patients (N=416) withdrew due to treatment-related adverse events1,2*
- Local side effects of Somatuline® Depot (lanreotide) Injection were mild to moderate and transient
- Gastrointestinal adverse events were also mild to moderate and were not dose-related
- Inhibition of gallbladder contractility is a known effect of the drug class of somatostatin analogs
Somatuline® Depot (lanreotide) Injection has a low incidence of cardiac adverse drug reactions
Most patients who experienced cardiac adverse events also had underlying cardiac disease.
Somatuline® Depot (lanreotide) Injection has a low incidence of hypoglycemia and hyperglycemia
Only 1.2% and 0.5% of patients reported hypoglycemia and hyperglycemia, respectively1,2*
* Pooled data from seven safety studies with Somatuline® Depot (lanreotide) Injection in 416 patients with acromegaly. One study was a fixed-dose pharmacokinetic study. The other six studies were open-label or extension studies. One study had a placebo-controlled run-in, and another had an active control. The median average monthly dose of Somatuline® Depot (lanreotide) Injection was 91.2 mg over 385 days with a median cumulative dose of 1,290 mg.
